Sema4 Holdings Corp.

Sema4 Holdings Corp.

SMFR

SMFRSema4 Holdings Corp. US flag

NASDAQ Global Select

0.31

USD

+0.07

- -

246.37MMarket Cap

Sema4 Holdings Corp.

SMFR

(NASDAQ Global Select)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Trellus Health plc (TRLS.L)
Veeva Systems Inc. (VEE.DE)
Optomed Oyj (OPTOMED.HE)
Lynx Global Digital Finance Corporation (LYNX.CN)
Oakridge International Limited (OAK.AX)
Opyl Limited (OPL.AX)
Business: Sema4 Holdings Corp. (SMFR), now operating as GeneDx Holdings Corp. (NASDAQ: WGS), provides genetic testing services focused on pediatric, rare disease, hereditary risk, and cancer diagnostics through whole exome and genome sequencing; it offers AI-based platforms for next-generation sequencing analysis, interpretation, and clinical reporting, including the Centrellis health intelligence platform for biopharma insights, drug discovery acceleration, pre-clinical and clinical trial support, advanced sequencing services, and analytics; additional services encompass Sema4 Signal for precision oncology from prevention to remission, carrier screening, noninvasive prenatal testing, newborn screening, hereditary cancer testing, and data services leveraging multidimensional genomic and clinical data. Founded in 2017 and headquartered in Stamford, Connecticut, the company serves healthcare providers, patients, health systems, and biopharma clients across the United States with operations including locations in New York and Maryland. In recent major changes, Sema4 acquired GeneDx from OPKO Health in 2022 for approximately $623 million in a combination of cash, stock, and milestones, strengthening its genomic capabilities; the company underwent a name change to GeneDx Holdings Corp. and shifted its ticker to WGS in January 2023 amid a strategic pivot to pediatric and rare disease testing, exiting reproductive health; it implemented restructuring with layoffs of about 700 employees, lab closures in Connecticut, and a focus on profitability by 2025, recently reporting strong Q2 2025 revenue growth of 69% in exome and genome testing.

Company News